Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2(+) breast cancer patients

Clinical benefits from trastuzumab and other anti-HER2 therapies in patients with HER2 amplified breast cancer remain limited by primary or acquired resistance. To identify potential mechanisms of resistance, we established trastuzumab-resistant HER2 amplified breast cancer cells by chronic exposure...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Scaltriti, Maurizio, Eichhorn, Pieter J., Cortés, Javier, Prudkin, Ludmila, Aura, Claudia, Jiménez, José, Chandarlapaty, Sarat, Serra, Violeta, Prat, Aleix, Ibrahim, Yasir H., Guzmán, Marta, Gili, Magui, Rodríguez, Olga, Rodríguez, Sonia, Pérez, José, Green, Simon R., Mai, Sabine, Rosen, Neal, Hudis, Clifford, Baselga, José
Format: Artigo
Sprache:Inglês
Veröffentlicht: National Academy of Sciences 2011
Schlagworte:
Biological Sciences
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3048107/
https://ncbi.nlm.nih.gov/pubmed/21321214
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1014835108
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge